Fylnetra (pegfilgrastim-pbbk), a biosimilar to Neulasta, is now available in the United States.

The US Food and Drug Administration (FDA) approved Fylnetra, a leukocyte growth factor, based on data demonstrating a high degree of similarity to the reference product, with no clinically meaningful differences.

Fylnetra is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia.

Continue Reading

Fylnetra is supplied as a 6 mg/0.6 mL preservative-free solution in single-dose prefilled syringes for subcutaneous injection.


Amneal launches third biosimilar with Fylnetra™ (pegfilgrastim-pbbk) in the United States. News release. Amneal. Accessed May 16, 2023. https://www.businesswire.com/news/home/20230516005033/en/Amneal-Launches-Third-Biosimilar-with-FYLNETRA%E2%84%A2-pegfilgrastim-pbbk-in-the-United-States

This article originally appeared on MPR